Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreReimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewGenerate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWElevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWOrchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety and quality.
COMPLIANCE OVERVIEWWhen your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWExplore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSAn in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTSBy making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MOREArtificial intelligence is accelerating opportunities. Realizing the benefits for healthcare requires the right expertise. Together, we can solve the problems of today, and drive the breakthroughs of tomorrow.
LEARN MOREThe IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MOREThe IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MOREIQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MOREIQVIA enables genomic research via global access to a network of genomic-clinical data, proprietary technologies that enable federated analytics, and therapeutic area & bioinformatics expertise to help you answer your most pressing research questions.
LEARN MOREOur mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.
LEARN MORECareers, culture and everything in between. Find out what’s going on right here, right now.
LEARN MORE"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.
SEARCH JOBSAs of 8th April 2020, the World Health Organization (WHO) has reported over 1,317,130 confirmed cases of COVID-19, with the coronavirus SARS-CoV-2 spreading from Wuhan, China to more than 200 countries and causing 74,306 deaths worldwide. The number of confirmed cases in recent outbreaks in the USA (363,321 cases), Italy (132,547) and Spain (135,032) have eclipsed the number of reported cases in China (83,157). Additional major outbreaks have occurred, initially in South Korea (10,384 cases) and Iran (62,589 cases), followed by many countries throughout Europe (Germany: 99,225; France: 73,488; UK: 51,612). Importantly, these figures reflect laboratory-confirmed cases, and the extent of testing has varied significantly between countries.
In Australia, a total of 5,956 cases have been detected from 313,000 tests as of 8th April 2020, resulting in 45 deaths. Nationally, most detected cases have been acquired overseas (56% of cases in Victoria, 60% in New South Wales and 78% in Queensland). Transmission to close contacts accounts for the majority of remaining cases, however locally-acquired cases with no identified contacts have occurred in all states, except Tasmania.
New South Wales (NSW) has the largest number of cases with no identified contacts (410; 15% of NSW cases). The greatest number of cases have occurred in NSW, however the rate of increase in Victoria (VIC) and Queensland (QLD) throughout most of March mirrored that of NSW, with the case burden in VIC and QLD 3-4 days behind the case numbers of NSW. However, in April the rate of new cases reported in all states and territories appears to have declined.